'This is the future of cancer treatment, we believe.' Eli Lilly CEO David Ricks said that Loxo Oncology has 'harnessed the power of emerging science' and that Lilly's acquisition of Loxo can help treat cancer globally.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Eli Lilly to Buy Loxo Oncology in Deal It Values at About $8 BillionEli Lilly said it is buying Loxo Oncology for $235 a share—a 68% premium from Friday’s closing price—in cash, a deal that expands the biopharmaceutical company’s oncology-treatment portfolio.
Baca lebih lajut »
Eli Lilly to buy Loxo Oncology in $8 billion cancer pushThe pharmaceutical company says it is buying Loxo Oncology for $235 a share in cash, a deal that expands the company’s cancer-treatment portfolio.
Baca lebih lajut »
Eli Lilly to spend about $8B on Loxo OncologyEli Lilly is spending about $8 billion in cash to buy Loxo Oncology, as the drugmaker bulks up on cancer treatments that target certain gene abnormalities. Loxo Oncology could launch a drug next year and targets an abnormality that occurs in several tumor types, including some lung and...
Baca lebih lajut »
Pharma giant Eli Lilly just made an $8 billion bet on a cutting-edge scientific approach that uses DNA to treat cancerEli Lilly's $8 billion acquisition of biotech Loxo Oncology is a notably large deal for Eli Lilly, but it could be done again, its CEO said.
Baca lebih lajut »
Lilly to buy Loxo Oncology in $8 billion cancer pushEli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 bill...
Baca lebih lajut »
Eli Lilly’s $8 bln cancer deal is a worthy wagerThe drug giant reckons it’ll take years to get a good return on its pricey acquisition of Loxo. But the upstart has had startling success figuring out why rare cancerous mutations occur, rather than where. Longer term, that should make for plenty of targets – and sticky prices.
Baca lebih lajut »
Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment
Baca lebih lajut »
Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & moreSome of the names on the move ahead of the open.
Baca lebih lajut »